Cargando…

Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?

BACKGROUND: The use of gold fiducial markers (FM) for prostate image-guided radiotherapy (IGRT) is standard practice. Published literature suggests low rates of serious infection following this procedure of 0-1.3%, but this may be an underestimate. We aim to report on the infection incidence and sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Loh, Jasmin, Baker, Katie, Sridharan, Swetha, Greer, Peter, Wratten, Chris, Capp, Anne, Gallagher, Sarah, Martin, Jarad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333155/
https://www.ncbi.nlm.nih.gov/pubmed/25890179
http://dx.doi.org/10.1186/s13014-015-0347-2
_version_ 1782357983268700160
author Loh, Jasmin
Baker, Katie
Sridharan, Swetha
Greer, Peter
Wratten, Chris
Capp, Anne
Gallagher, Sarah
Martin, Jarad
author_facet Loh, Jasmin
Baker, Katie
Sridharan, Swetha
Greer, Peter
Wratten, Chris
Capp, Anne
Gallagher, Sarah
Martin, Jarad
author_sort Loh, Jasmin
collection PubMed
description BACKGROUND: The use of gold fiducial markers (FM) for prostate image-guided radiotherapy (IGRT) is standard practice. Published literature suggests low rates of serious infection following this procedure of 0-1.3%, but this may be an underestimate. We aim to report on the infection incidence and severity associated with the use of transrectally implanted intraprostatic gold FM. METHODS: Three hundred and fifty-nine patients who underwent transrectal FM insertion between January 2012 and December 2013 were assessed retrospectively via a self-reported questionnaire. All had standard oral fluoroquinolone antibiotic prophylaxis. The patients were asked about infective symptoms and the treatment received including antibiotics and/or related hospital admissions. Potential infective events were confirmed through medical records. RESULTS: 285 patients (79.4%) completed the questionnaire. 77 (27.0%) patients experienced increased urinary frequency and dysuria, and 33 patients (11.6%) reported episodes of chills and fevers after the procedure. 22 patients (7.7%) reported receiving antibiotics for urinary infection and eight patients (2.8%) reported hospital admission for urosepsis related to the procedure. CONCLUSION: The overall rate of symptomatic infection with FM implantation in this study is 7.7%, with one third requiring hospital admission. This exceeds the reported rates in other FM implantation series, but is in keeping with the larger prostate biopsy literature. Given the higher than expected complication rate, a risk-adaptive approach may be helpful. Where higher accuracy is important such as stereotactic prostate radiotherapy, the benefits of FM may still outweigh the risks. For others, a non-invasive approach for prostate IGRT such as cone-beam CT could be considered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-015-0347-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4333155
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43331552015-02-20 Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks? Loh, Jasmin Baker, Katie Sridharan, Swetha Greer, Peter Wratten, Chris Capp, Anne Gallagher, Sarah Martin, Jarad Radiat Oncol Research BACKGROUND: The use of gold fiducial markers (FM) for prostate image-guided radiotherapy (IGRT) is standard practice. Published literature suggests low rates of serious infection following this procedure of 0-1.3%, but this may be an underestimate. We aim to report on the infection incidence and severity associated with the use of transrectally implanted intraprostatic gold FM. METHODS: Three hundred and fifty-nine patients who underwent transrectal FM insertion between January 2012 and December 2013 were assessed retrospectively via a self-reported questionnaire. All had standard oral fluoroquinolone antibiotic prophylaxis. The patients were asked about infective symptoms and the treatment received including antibiotics and/or related hospital admissions. Potential infective events were confirmed through medical records. RESULTS: 285 patients (79.4%) completed the questionnaire. 77 (27.0%) patients experienced increased urinary frequency and dysuria, and 33 patients (11.6%) reported episodes of chills and fevers after the procedure. 22 patients (7.7%) reported receiving antibiotics for urinary infection and eight patients (2.8%) reported hospital admission for urosepsis related to the procedure. CONCLUSION: The overall rate of symptomatic infection with FM implantation in this study is 7.7%, with one third requiring hospital admission. This exceeds the reported rates in other FM implantation series, but is in keeping with the larger prostate biopsy literature. Given the higher than expected complication rate, a risk-adaptive approach may be helpful. Where higher accuracy is important such as stereotactic prostate radiotherapy, the benefits of FM may still outweigh the risks. For others, a non-invasive approach for prostate IGRT such as cone-beam CT could be considered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-015-0347-2) contains supplementary material, which is available to authorized users. BioMed Central 2015-02-13 /pmc/articles/PMC4333155/ /pubmed/25890179 http://dx.doi.org/10.1186/s13014-015-0347-2 Text en © Loh et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Loh, Jasmin
Baker, Katie
Sridharan, Swetha
Greer, Peter
Wratten, Chris
Capp, Anne
Gallagher, Sarah
Martin, Jarad
Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?
title Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?
title_full Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?
title_fullStr Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?
title_full_unstemmed Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?
title_short Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?
title_sort infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks?
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333155/
https://www.ncbi.nlm.nih.gov/pubmed/25890179
http://dx.doi.org/10.1186/s13014-015-0347-2
work_keys_str_mv AT lohjasmin infectionsafterfiducialmarkerimplantationforprostateradiotherapyareweunderestimatingtherisks
AT bakerkatie infectionsafterfiducialmarkerimplantationforprostateradiotherapyareweunderestimatingtherisks
AT sridharanswetha infectionsafterfiducialmarkerimplantationforprostateradiotherapyareweunderestimatingtherisks
AT greerpeter infectionsafterfiducialmarkerimplantationforprostateradiotherapyareweunderestimatingtherisks
AT wrattenchris infectionsafterfiducialmarkerimplantationforprostateradiotherapyareweunderestimatingtherisks
AT cappanne infectionsafterfiducialmarkerimplantationforprostateradiotherapyareweunderestimatingtherisks
AT gallaghersarah infectionsafterfiducialmarkerimplantationforprostateradiotherapyareweunderestimatingtherisks
AT martinjarad infectionsafterfiducialmarkerimplantationforprostateradiotherapyareweunderestimatingtherisks